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Background: The migration of T cell to atherosclerotic lesions is proposed to be involved in the pathogenesis of
the atherosclerosis. Sphingosine 1-phosphate (S1P), a bioactive lysophospholipid released from activated platelets,
exerts a variety of responses such as cell migration and proliferation, and reportedly induces T cell migration.
Accordingly, platelet-T cell interactions may exist based on T cell responses triggered by platelet-derived S1P.
Methods: S1P was measured using two-step lipid extraction followed by high-performance liquid chromatography
(HPLC) separation while other phospholipids were determined by an enzymatic assay. The expression of S1P and
lysophosphatidic acid receptors on Jurkat T cells was examined by RT-PCR and flow cytometry. Jurkat cell migration
by S1P and the supernatant of activated platelets (SAP) was evaluated by a modified Boyden’s chamber assay.
Results: S1P1 receptor was confirmed to be expressed on Jurkat T cell by RT-PCR and flow cytometry. S1P at
10-100 nM induced strong Jurkat cell migration, which was inhibited by the S1P1 (and S1P3) antagonist VPC23019
and the Gi inactivator pertussis toxin (PTX). We found that the supernatant (releasate) of human platelets activated
by collagen stimulation, which contains S1P abundantly, induced Jurkat cell migration and that the migration was
inhibited by VPC23019 and PTX. In addition, human serum, into which platelet contents (including S1P) are fully
released, induced the Jurkat cell migration, which was also inhibited by VPC23019.
Conclusions: Our findings suggest that platelet-derived S1P induces Jurkat T cell migration possibly via S1P1. S1P
may be a key molecule involved in the responses triggered by platelet-T cell interactions, including atherosclerosis.
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Lysophospholipids, such as sphingosine 1-phosphate (S1P),
lysophosphatidic acid (LPA), lysophosphatidylserine (LPS),
lysophosphatidylinositol (LPI), lysophosphatidylethanola-
mine (LPE), are important lipid mediators involved in vari-
ous physiological and pathophysiological events. Among
these lipid mediators, much research has been conducted
with LPA and S1P, and their important role at an individual
level has been confirmed. S1P not only serves as an inter-
mediate metabolite linking sphingolipids and glyceropho-
spholipids, but also exerts strong biological responses,
through the S1P receptors expressed on a variety of cell* Correspondence: yatoyuta-tky@umin.ac.jp
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unless otherwise stated.types, including lymphocytes and endothelial cells [1]. More
recently, S1P has been shown to facilitate the migration of
lymphocytes, particularly T lymphocytes, and S1P signaling
has been therapeutically targeted in the treatment of remit-
ting, relapsing multiple sclerosis. Indeed, the sphingosine
analogue Fingolimod, also known as FTY720, has been
approved by the US Food and Drug Administration for
the treatment of multiple sclerosis [2,3]. FTY720 is phos-
phorylated by sphingosine kinase 2 to FTY720-P, which
markedly reduces the number of circulating lymphocytes
in peripheral blood, through downregulation of S1P1. In
this way, S1P has been focused as a new therapeutic target,
and new clinical applications are expected to be available
by the development of receptor specific agonist/antagonist
or inhibitors of the enzyme involved in S1P metabolism.
The S1P present in the circulation is believed to be
mainly derived from erythrocytes, platelets, and vascular. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
g/publicdomain/zero/1.0/) applies to the data made available in this article,
Iino et al. Lipids in Health and Disease 2014, 13:150 Page 2 of 10
http://www.lipidworld.com/content/13/1/150endothelial cell [4]. Although erythrocytes are believed to
determine the plasma S1P level during the steady state
in healthy subjects [5-7], the fact that platelets contain
S1P abundantly and release it through activation [8,9],Figure 1 Measurement of platelet-derived S1P. Chromatograms of the
(A) and absence of C17-S1P (B). Chromatogram of the supernatant from ac
C17-S1P and S1P, respectively.indicates that S1P derived from activated platelets may
play an important role during pathological states in which
platelets are activated, such as thrombotic conditions.
Atherosclerosis is a chronic inflammatory and thromboticcalibration standard lipids, i.e., C17-S1P (internal standard) and S1P
tivated platelets from a healthy volunteer (C). Peaks 1 and 2 represent
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out the various stages of atherogenesis. Recently, the in-
volvement of T cell in this process has been also
clarified. T cells are detected even in the early athero-
sclerotic lesions, their numbers increasing with progres-
sion of the lesions, and most of these T cells has been
shown to be CD4+ T lymphocytes [10]. Several groups
have been working in the characterization of the patho-
genic T cell subsets [11]. Moreover, the importance of T
cells in atherogenesis has been highlighted by animal
studies showing that transfer of CD4+ T cells aggravates
[12], whilst CD4+ T cell deficiency attenuates athero-
sclerosis in apoE-/- mice [13].
In this study, we focused on the effect of S1P on T cell
migration, and using Jurkat cells, a human acute lympho-
blastic leukemia cell line, as a model, we investigated the
involvement of platelet-derived S1P in the cross-talk be-
tween platelets and lymphocytes, in comparison with
the other lysophospholipids, assuming the pathological
thrombogenic condition.Results
Concentration of S1P and other related lipid mediators
released from activated platelets
We first confirmed lysophospholipids released from
platelets. Human washed platelets were stimulated with
20 μg/mL of collagen, and the concentration of S1P in
the supernatant was measured. The ortho-phthalalde-
hyde (OPA) derivatives of S1P were separated by HPLC
and monitored by fluorescence. The concentration of S1P
in the supernatant prepared from activated platelets (5.0 ×
108 /mL) was calculated as 0.36 ± 0.11 μM. The chromato-
grams of calibration standard and platelet derived S1P are
shown in Figure 1. The S1P release was found to be colla-
gen concentration-dependent (data not shown). We also
analyzed the concentration of other related lipid media-
tors, namely total phospholipid, LPA and lysophosphati-
dylcholine (LPC) (Table 1). Autotaxin (ATX), possessing
lysophospholipase D activity, produces LPA from LPC,
and both LPA and LPC exist in the activated platelet
supernatant. The involvement of ATX in the LPA produc-
tion in this system, however, remains to be solved.Table 1 The concentration of total phospholipid, S1P, LPA,
and LPC from human platelets activated with collagen
Concentrations (μM)*
Total phospholipid 11.07 ± 1.96
S1P 0.36 ± 0.11
LPA 0.45 ± 0.21
LPC 4.0 ± 1.41
*mean ± SD (n = 4).Expression of S1P receptors and LPA receptors on Jurkat cells
Next, we confirmed the expression of S1P and LPA re-
ceptors on Jurkat cells by RT-PCR. As shown in Figure 2-A,
Jurkat cells expressed the mRNA transcripts for S1P1,
S1P2, S1P3, and S1P4. S1P5 mRNA was hardly detectable.
In flow-cytometry, we confirmed the expression of S1P1 at
the protein level (Figure 2-B).
On the other hand, Jurkat cells also expressed LPA1,
LPA2, LPA3, and LPA4 (Figure 2-A).
Induction of Jurkat cell migration by S1P and the
supernatant of activated human platelets and its reversal
by PTX and VPC23019
First, the migration of Jurkat cell was evaluated by a modi-
fied Boyden’s chamber assay, and the concentrations of
S1P leading cells to migrate were confirmed. A marked
migration of Jurkat cells was observed with S1P concentra-
tion from 10 nM to 100 nM (Figure 3-A), and the migra-
tion induced by 100 nM S1P was inhibited by the Gi
inactivator PTX (Figure 3-B), and by the VPC23019, in a
concentration-dependent manner, with approximately 25%
inhibition at 20 μM, and 75% at 50 μM (Figure 3-C). We
also evaluated the migration of Jurkat cells in the presence
of lysophospholipids other than S1P. In contrast with S1P,
LPA, LPI, and LPS did not induce the migration of Jurkat
cells (Figure 4).
Next, similar experiments were performed using the
supernatant of collagen-activated human platelets at a
10-fold dilution. The supernatant induced a strong mi-
gration of the Jurkat cells (Figure 5-A), which was also
observed when the supernatant was boiled, indicating
that the agent responsible for this response was a lipid,
but not peptide, mediator (Figure 5-B & C). The migra-
tion induced by the supernatant of activated human
platelets was inhibited, although not completely, by PTX
(Figure 5-B) and VPC23019 at 50 μM (Figure 5-C).
Induction of Jurkat cell migration by human serum and
its reversal by VPC23019
Finally, we evaluated the migratory response of Jurkat
cells induced by human serum, into which platelets con-
tents (including S1P) are fully released. Serum-induced
Jurkat cell migration was observed; the highest response
was observed with 10-fold diluted serum, followed by
100-fold diluted serum. The migratory response induced
by 100-fold diluted serum was inhibited by VPC23019,
as was the case with S1P (Figure 6).
Discussion
In this study, among the various effects of S1P, we particu-
larly focused on the cell migration responses, and con-
firmed the induction of the migratory ability of Jurkat
cells, used as the model of T lymphocytes, by S1P released
from activated platelets.
Figure 2 Expression of S1P and LPA receptors in Jurkat cells. (A) The expression of S1Ps and LPAs in Jurkat cells was examined by RT-PCR.
The amplified products for the Jurkat mRNAs for S1P and LPA receptors were resolved in a 2.5% agarose gel. MW indicates the molecular size
markers. mRNA transcripts for S1P1, S1P2, S1P3, and S1P4, were found, but that of S1P5 could be hardly detected. Also, LPA1, LPA2, LPA3, and LPA4
were expressed. (B) The surface expression of S1P1 in Jurkat cells was examined by flow-cytometry. Horizontal axis indicates the strength of S1P1
expression as assessed by the indirect FITC fluorescence intensity. The bold line histogram represents staining with anti-S1P1 antibody, while the
narrow line represents the negative control. S1P1 was found expressed on Jurkat cells.
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lets (5.0 × 108 /mL), the concentrations of S1P and LPA
were found to be 0.36 ± 0.11 μM, and 0.45 ± 0.21 μM, re-
spectively. It is reported that 141 ± 4 pmol S1P is stored
in 108 platelets [8], and hence mathematically, 51% of
S1P stored in platelets was released extracellularly. This
figure is reasonable since collagen is a strong platelet
agonist. Further, it is reported that human plasma con-
tains about 190 nM S1P, while about 480 nM is present
in serum [8], and this difference may be dependent on
the activation of platelets.
Under the patho-physiological conditions, such as ath-
erosclerosis, which are associated with thrombosis and
platelets activation, the release of lipid mediators is ex-
pected to occur. As our results indicate, the other cell
types, such as lymphocytes, endothelial cells, macro-
phages, and smooth muscle cells, which are also involvedin the atherosclerotic process, are exposed to S1P released
by activated platelets, and are stimulated to migrate. S1P
and LPA act mainly through a G protein-coupled cell sur-
face receptors, and as we have confirmed, these receptors
are expressed on the Jurkat cells at the mRNA level. S1P1
expression was also confirmed on Jurkat T cells by flow-
cytometry. We observed that S1P, but not LPA, induced
the migration of Jurkat cells, in the modified Boyden’s
chamber assay. The migratory ability of Jurkat cells in-
duced by S1P was inhibited by the S1P1 (and S1P3) antag-
onist VPC23019 and by the Gi inactivator PTX, as
previously reported, confirming the involvement of the
S1P1 and the Gi signaling pathway. Similarly, the super-
natant of activated human platelets also induced the mi-
gration of Jurkat cells. This response was preserved either
after the heat-treatment of the supernatant, confirming
that the mediators released from activated platelets and
Figure 3 Jurkat cell migration induced by S1P. (A) Jurkat cells were seeded into the upper well of the Transwell cell culture chambers, and
allowed to migrate to the lower chamber, where various concentrations of S1P were placed, for 4 h. A bell-shape pattern of migration was
observed, with a dose-dependent increase of migration with S1P from 0.1 – 100 nM, but decreasing with S1P 1 μM. (B) Jurkat cells, pretreated
without (open column) or with (solid column) 200 ng/mL of PTX for 60 min, were allowed to migrate toward the indicated concentrations of
100 nM S1P (n = 4). PTX pretreatment inhibited the migration of Jurkat cells induced by S1P. Statistically significant compared to control cells,
i.e., without PTX treatment. (C) Jurkat cells pretreated without (open column) or with 20 μM (solid column) or with 50 μM (hatched column) of
VPC23019 for 60 min were allowed to migrate toward 100 nM S1P (n = 3). VPC23019 at 50 μM, but not 20 μM, significantly inhibited migration of
Jurkat cells induced by S1P. *Statistically significant compared to control cells, i.e., without VPC23019 treatment (P < 0.01).
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protein, components. Further, when the concentration
S1P in the supernatant prepared from activated platelets
was calculated (extrapolated), it corresponded to the con-
centration of S1P that induced cell migration, and this
response was also inhibited by VPC23019 and PTX. It
has been reported that S1P1, S1P2, S1P3, and S1P4 are
expressed on Jurkat cells, and S1P1 and S1P4 are the mainly
expressed on human T lymphocytes [14]. From our experi-
ment using VPC23019, although the involvement of other
receptors cannot be completely denied, we considered that
S1P1 is the mostly involved in the migratory response of T
lymphocytes induced by the S1P present in the supernatant
of activated platelets.
Similar results are obtained with serum, into which
platelets contents (including S1P) are fully released.
Measurements of serum concentration of S1P have beenextensively performed in our lab, and from our data, the
100-fold diluted serum is known to contain about
10 nM of S1P. Accordingly, 100-fold diluted serum in-
duced the migratory response of Jurkat cells, which was
suppressed by VPC23019. However, this inhibitory effect
of VPC23019 could not be obtained when cells were
stimulated with 10-fold diluted serum. From these find-
ings, it is suggestive that S1P, although not exclusive,
plays a pivotal role in the migratory response induced by
human serum.
So far, the antagonistic effects of S1P, either by stimulat-
ing or inhibiting the process of arteriosclerosis, have been
reported. From our present data, it can be suggested that
the S1P, released by platelets in the atherosclerotic lesion or
other conditions in which platelets accumulate, induces
T cells migration and accumulation, accelerating the
pathogenesis of the disease. The clinical implications of
Figure 4 Jurkat cell migration induced by S1P, LPA, LPI or LPS.
Jurkat cells were seeded into the upper chamber of the Transwell
cell culture chambers, and allowed to migrate to the lower
chamber, where 100 nM S1P, LPA, LPI or LPS were placed, for 4 h.
S1P was the only mediator able to induce migration of Jurkat cells.
*Statistically significant compared to cells migrating to well without
mediators (P < 0.01).
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released from activated platelets remain to be eluci-
dated. In in vitro studies, however, aspirin and two
structurally unrelated reversible cyclooxygenase inhibi-
tors diclofenac and ibuprofen suppressed S1P release.
Moreover, oral aspirin intake reportedly attenuated S1P
release from platelets in healthy human volunteers
ex vivo [15]. Further clinical studies are needed to eluci-
date the importance of local S1P released from platelets
and its effects on T cells in vivo.
The relationship between atherosclerosis and T cells has
already been reported. T cells infiltration is observed even
in the early atherosclerotic lesions, their number increas-
ing with the progression of disease; CD4+ T cells are the
most abundantly found in atherosclerotic lesions [10]. Sev-
eral groups have characterized the pathogenic T cell sub-
sets in the arteriosclerotic lesion [11]. Among CD4+ T
cells, Th1 cells are pro-atherogenic, while Treg cells are
anti-atherogenic and the role of Th2 and Th17 cells re-
mains unknown [16]. Moreover, the importance of T cells
in atherogenesis has been highlighted by animal studies
showing that transfer of CD4+ T cells aggravates [12],
whilst depletion of CD4+ T cells attenuates atherosclerosis
in apoE-/- mice [13]. Meanwhile, S1P suppressed the cell
migration induced by the chemokines CXCL4 and CXCL-
1 [17]. Our results indicated that the concentration of S1P
in activated platelet supernatant was consistent with that
of purified S1P required to induce migration of Jurkat cell.
These facts strongly suggest the involvement of platelet-
derived S1P in the pathogenesis of atherosclerosis and the
cell-cell interaction between platelets and T lymphocytes
through S1P.
Besides atherosclerosis, there are reports on the
pathophysiological interaction between platelets and Tlymphocytes (lymphocytes). Interaction of platelets with T
cells and B cells can contribute to vasculopathy in trans-
plants [18]. Patients with systemic lupus erythematosus
(SLE), a condition associated with abnormality of lympho-
cytes, have been shown to have higher levels of platelet
microparticles, CD62P expression, and annexin V com-
pared to control [19]. Platelet-lymphocyte interaction also
plays a role in rheumatoid arthritis [20], inflammation in
obesity [21], and reperfusion-induced inflammation after
cardio-pulmonary bypass (CPB) [22]. Thus, there is the
possibility that S1P released by activated platelets induces
the platelet-lymphocyte interaction, which is involved in
the pathogenesis of arteriosclerosis as well as other clinical
conditions, but further research is necessary to confirm
these facts.
As referred to in the INTRODUCTION, the S1P1
modulator FTY720 has been approved for the treatment
of multiple sclerosis, and it has been reported that this
agent exerts atheroprotective effects in mice model. Oral
FTY720 treatment reportedly results in inhibition of ath-
erosclerosis development in mice via inhibition of effector
T responses and induction of a regulatory T-cell response
[23]. FTY720 inhibits atherosclerosis by suppressing the
machinery involved in monocyte/macrophage emigration
to atherosclerotic lesions [24], and by modulating lympho-
cyte and macrophage function [25]. These findings suggest
that FTY720 may represent a new therapeutic approach to
atherosclerosis, which is consistent with our present study.
In addition to being an important regulator of lympho-
cytes in the circulation, our results suggest the import-
ant role of S1P for recruiting T lymphocytes at the site




Sphingosine 1-phosphate, and D-erythro (S1P) were
purchased from Enzo Life Sciences (Plymouth Meet-
ing, PA). C17-sphingosine 1-phosphate (C17-S1P), lyso-
phosphatidic acid (LPA), lysophosphatidylserine (LPS),
lysophosphatidylinositol (LPI), and VPC23019 were
purchased from Avanti Polar Lipids Inc (Alabaster,
AL). Pertussis toxin (PTX) was obtained from Wako
Pure Chemical Industries (Osaka, Japan).
S1P, LPA, LPS and LPI were dissolved in methanol.
Just before use, the methanol was evaporated and the re-
agents were resolved in PBS containing 0.4% fatty acid-
free BSA (Sigma-Aldrich Co., St. Louis, MO). C17-S1P
was dissolved in methanol. VPC23019 and PTX were
dissolved in DMSO.
Cell culture
The human T-cell leukemia Jurkat cells were maintained
in RPMI 1640 (Nacalaitesque, Inc. Kyoto, Japan) with
Figure 5 Jurkat cell migration induced by the supernatant from activated platelets (SAP). (A) Jurkat cells were seeded into the upper
chamber of the Transwell cell culture chambers, and allowed to migrate for 4 h to the lower chamber, where the supernatant from activated
platelets, at various concentrations, were placed. A bell-shape migration pattern was observed, with a dose-dependent increase of migration with
the supernatant at 1-fold to 10-fold dilution, and decreasing thereafter at 100-fold and 1000-fold dilution. (B) Jurkat cells pretreated without
(open column) or with (solid column) 200 ng/mL of PTX for 60 min were allowed to migrate toward the indicated concentrations of either heat
(100°C)-treated or -untreated supernatant of activated platelets (10-fold dilutions), for 4 h (n = 3). Both heat-treated and –untreated supernatants
induced the migration of Jurkat cells, which was inhibited by PTX pretreatment. *Statistically significant compared without PTX treatment
(P < 0.01). (C) Jurkat cells pretreated without (open column) or with (solid column) 50 μM of VPC23019 for 60 min were allowed to migrate
toward either heat (100°C)-treated or –untreated supernatant of activated platelets (10-fold dilutions) (n = 3). VPC23019 inhibited the migration of
Jurkat cells induced by the supernatant of activated platelets, either heat-treated or –untreated. *Statistically significant compared to
VPC23019-untreated cells (P < 0.01).
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mycotics at 37°C under an atmosphere of 5% CO2 and
95% room air.
Platelet sample preparation
Platelets were isolated from the venous blood of healthy
adult volunteers, who had agreed to participate and had
given informed consent. Human washed platelets (at a cell
density of 5.0 × 108/mL) were prepared as previously de-
scribed [26], and stimulated with 20 μg/ml of type I colla-
gen (collagen reagent Horm; Nycomed, Munich, Germany)
for 15 min under continuous stirring at 1,000 r.p.m. The
samples were then centrifuged at 10,000 r.p.m for 1 min,and the resultant supernatants were used to stimulate
Jurkat T cells.
Measurement of S1P
The contents of S1P in the supernatant of platelets were
determined using two-step lipid extraction followed by
HPLC separation, as described previously [27]. Briefly,
samples were sonicated in 3 mL of methanol/chloroform
(2:1) with internal standard for 30 min. After adding
2 mL of chloroform, 2.1 mL of 1 mM KCl, and 100 μL
of 3N NaOH, samples were centrifuged and the alkaline
upper phase (3.8 mL) was collected to new tubes, to
which 4 mL of chloroform and 200 μL of concentrated
Figure 6 Induction of Jurkat cell migration by human serum
and its reversal by VPC23019. Jurkat cells pretreated without
(open column) or with (solid column) 50 μM of VPC23019 for
60 min were allowed to migrate toward the indicated
concentrations of human serum (100-fold dilutions and 10-fold
dilutions) (n = 3). Human serum induced strong and dose-
dependent migration of Jurkat cells, and the migration induced by
human serum at a 100-fold dilution was comparable to that induced
by S1P at 100 nM. VPC23019 significantly inhibited the migratory
response induced by S1P and human serum at 100-fold dilution, but
not that induced by human serum at 10-fold dilution. *Statistically
significant compared to cells without VPC23019 pretreatment
(P < 0.01).
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(3.5 mL) formed under nitrogen gas and resolved in
methanol, followed by HPLC separation with TSKgel
ODS-80TM column (Tosoh, Tokyo, Japan). For the
measurement of S1P content, we used C17-S1P as an
internal standard.
Quantitation of related lipids
Choline-containing phospholipids and LPC in the sample
were measured using commercially available enzymatic
assay kits: AZWELL LPC Assay Kit (Alfresa Pharma,
Osaka, Japan) and Nescauto PL-V2 (Alfresa Pharma, Osaka,
Japan), respectively. These phospholipid measurementsTable 2 List of primers









LPA4 NM005296 AAAGATCATGTACCCAATGACCTTwere performed using a Hitachi 7600 analyzer (Hitachi,
Tokyo, Japan). The concentration of LPA was determined
by an enzymatic cycling assay, as described previously [28].
RNA isolation and RT-PCR
Total RNA was prepared from Jurkat cells with the total
RNA isolation system, ISOGEN (Nippon Gene, Tokyo,
Japan). The total RNA (1 μg) was then reverse transcribed
using a Transcriptor First Strand cDNA Synthesis Kit
(Roche Diagnostics, Tokyo, Japan). The reverse-transcribed
complementary DNA was then amplified in a GeneAmp
PCR system 9700 (Applied Biosystems, CA, USA). Oligo-
nucleotide primer pairs used for S1P1, S1P2, S1P3, S1P4,
S1P5, LPA1, LPA2, LPA3, LPA4. The primer sequences were
shown in details in Table 2. The amplification was con-
ducted with 35 cycles of 30 sec at 95°C, 30 sec at 55°C and
30 sec at 72°C (S1P1, S1P2), 35 cycles of 30 sec at 95°C,
30 sec at 60°C and 30 sec at 72°C (S1P3, S1P4, S1P5, LPA2),
40 cycles of 30 sec at 95°C, 30 sec at 55°C and 30 sec at
72°C (LPA1, LPA3, LPA4). The PCR products were re-
solved by electrophoresis on a 2.5% agarose gel, and then
stained with ethidium bromide.
Flow cytometry (S1P1 expression)
To examine the S1P1 expression of Jurkat cells, cultured
cells were collected and incubated with anti-S1P1 poly-
clonal antibody [S1P1: Anti-S1P Receptor1 (EDG-1) rabbit
polyclonal antibody] (Biomol, Plymouth Meeting, PA,
USA). After incubation, the cells were treated with FITC
labeled goat anti-rabbit IgG as the second antibody. The
number of cells showing positive expression of S1P1 was
analyzed by FACS flow cytometry (Becton–Dickinson).
Migration assay
Jurkat cell migration was assessed by means of a modi-
fied Boyden’s chamber assay, i.e., in Transwell cell cul-
ture chambers (Costar, Cambridge, MA). Polycarbonate
filters with 8 μm pores, used to separate the upper and
lower chambers, were coated with collagen Type I solu-
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and dried immediately. Then Jurkat cells were added to
the upper compartment of the chamber at a density of
1.0 × 107/mL (1.0 × 106 per 100 μL) of medium contain-
ing 0.1% fatty acid free bovine serum albumin and incu-
bated for 4 h at 37°C. The Jurkat cells were allowed to
migrate toward an indicated reagent (S1P and super-
natant of activated platelets; 600 μL) in the lower cham-
ber. After the reaction, migrated cells were collected
from the bottom chamber, washed, resuspended in
250 μL and counted by flow cytometry for 1 min. Each
determination represents the average of two individual
migration chambers. When indicated, cells were prein-
cubated with 20 μM, 50 μM VPC23019 or 200 ng/mL
PTX for 60 min.
Statistics
The results were expressed as the mean ± SD. Where in-
dicated, the statistical significance of the differences be-
tween two groups was determined by a paired Student’s
t test. P < 0.01 was considered to denote significance.
Abbreviations
ATX: Autotaxin; HPLC: High-performance liquid chromatography;
LPA: Lysophosphatidic acid; LPC: Lysophosphatidylcholine;
LPE: Lysophosphatidylethanolamine; LPI: Lysophosphatidylinositol;
LPS: Lysophosphatidylserine; OPA: Ortho-phthalaldehyde; PTX: Pertussis toxin;
SAP: The supernatant from activated platelets; S1P: Sphingosine 1-phosphate.
Competing interests
The authors declare that they have no competing interests.
Authors’ contribution
JI and MO participated in study design, carried out experiments and data
analysis, and drafted the initial manuscript. MKu and MKa participated in
several experiments. RO participated in measurement of lysophospholipids.
YS participated in quantitative RT-PCR. SO, YO, NT and MT were involved in
study design and drafting manuscript. YY conceived of the study,
coordinated the study design and helped to draft the manuscript. All authors
read and approved the final manuscript.
Acknowledgements
This research was supported by JSPS KAKENHI Grant Numbers 22249017,
25253040 (Y.Y) and 23931007 (J.I).
Author details
1Department of Clinical Laboratory, The University of Tokyo Hospital, Tokyo,
Japan. 2Department of Clinical Laboratory Medicine, Graduate School of
Medicine, The University of Tokyo, Tokyo, Japan. 3Analytical Laboratory
Chemistry, Graduate School of Health Care Sciences, Tokyo Medical and
Dental University, Tokyo, Japan. 4Department of Clinical and Laboratory
Medicine, Faculty of Medicine, University of Yamanashi, Yamanashi, Japan.
5Department of Transfusion Medicine, The University of Tokyo, Tokyo, Japan.
Received: 3 July 2014 Accepted: 19 September 2014
Published: 25 September 2014
References
1. Hannun YA, Obeid LM: Principles of bioactive lipid signalling: lessons
from sphingolipids. Nat Rev Mol Cell Biol 2008, 9:139–150.
2. Cohen JA, Barkhof F, Comi G, Hartung HP, Khatri BO, Montalban X, Pelletier J,
Capra R, Gallo P, Izquierdo G, Tiel-Wilck K, de Vera A, Jin J, Stites T, Wu S,
Aradhye S, Kappos L, TRANSFORMS Study Group: Oral fingolimod or
intramuscular interferon for relapsing multiple sclerosis. N Engl J Med 2010,
362:402–415.3. Kappos L, Radue EW, O’Connor P, Polman C, Hohlfeld R, Calabresi P, Selmaj K,
Agoropoulou C, Leyk M, Zhang-Auberson L, Burtin P, FREEDOMS Study Group:
A placebo-controlled trial of oral fingolimod in relapsing multiple sclerosis.
N Engl J Med 2010, 362:387–401.
4. Venkataraman K, Lee YM, Michaud J, Thangada S, Ai Y, Bonkovsky HL,
Parikh NS, Habrukowich C, Hla T: Vascular endothelium as a contributor of
plasma sphingosine 1-phosphate. Circ Res 2008, 102:669–676.
5. Pappu R, Schwab SR, Cornelissen I, Pereira JP, Regard JB, Xu Y, Camerer E,
Zheng YW, Huang Y, Cyster JG, Coughlin SR: Promotion of lymphocyte
egress into blood and lymph by distinct sources of sphingosine-1-
phosphate. Science 2007, 316:295–298.
6. Hänel P, Andréani P, Gräler MH: Erythrocytes store and release
sphingosine 1-phosphate in blood. FASEB J 2007, 21:1202–1209.
7. Ohkawa R, Nakamura K, Okubo S, Hosogaya S, Ozaki Y, Tozuka M, Osima N,
Yokota H, Ikeda H, Yatomi Y: Plasma sphingosine-1-phosphate measurement
in healthy subjects: close correlation with red blood cell parameters.
Ann Clin Biochem 2008, 45:356–363.
8. Yatomi Y, Igarashi Y, Yang L, Hisano N, Qi R, Asazuma N, Satoh K, Ozaki Y,
Kume S: Sphingosine 1-phosphate, a bioactive sphingolipid abundantly
stored in platelets, is a normal constituent of human plasma and serum.
J Biochem 1997, 121:969–973.
9. Yatomi Y, Ohmori T, Rile G, Kazama F, Okamoto H, Sano T, Satoh K, Kume S,
Tigyi G, Igarashi Y, Ozaki Y: Sphingosine 1-phosphate as a major bioactive
lysophospholipid that is released from platelets and interacts with
endothelial cells. Blood 2000, 96:3431–3438.
10. Hansson GK: Immune mechanisms in atherosclerosis. Arterioscler Thromb
Vasc Biol 2001, 21:1876–1890.
11. Tedgui A, Mallat Z: Cytokines in atherosclerosis: pathogenic and
regulatory pathways. Physiol Rev 2006, 86:515–581.
12. Zhou X, Nicoletti A, Elhage R, Hansson GK: Transfer of CD4(+) T cells
aggravates atherosclerosis in immunodeficient apolipoprotein E
knockout mice. Circulation 2000, 102:2919–2922.
13. Zhou X, Robertson AK, Rudling M, Parini P, Hansson GK: Lesion
development and response to immunization reveal a complex role for
CD4 in atherosclerosis. Circ Res 2005, 96:427–434.
14. Gräler MH, Goetzl EJ: The immunosuppressant FTY720 down-regulates
sphingosine 1-phosphate G-protein-coupled receptors. FASEB J 2004,
18:551–553.
15. Ulrych T, Böhm A, Polzin A, Daum G, Nüsing RM, Geisslinger G, Hohlfeld T,
Schrör K, Rauch BH: Release of sphingosine-1-phosphate from human
platelets is dependent on thromboxane formation. J Thromb Haemost
2011, 9:790–798.
16. Tse K, Tse H, Sidney J, Sette A, Ley K: T cells in atherosclerosis. Int Immunol
2013, 25:615–622.
17. Graeler M, Shankar G, Goetzl EJ: Cutting edge: suppression of T cell
chemotaxis by sphingosine 1-phosphate. J Immunol 2002, 169:4084–4087.
18. Morrell CN, Sun H, Swaim AM, Baldwin WM: Platelets an inflammatory
force in transplantation. Am J Transplant 2007, 7:2447–2454.
19. Nagahama M, Nomura S, Ozaki Y, Yoshimura C, Kagawa H, Fukuhara S:
Platelet activation markers and soluble adhesion molecules in patients
with systemic lupus erythematosus. Autoimmunity 2001, 33:85–94.
20. Milovanovic M, Nilsson E, Järemo P: Relationships between platelets and
inflammatory markers in rheumatoid arthritis. Clin Chim Acta 2004,
343:237–240.
21. Nishimura S, Manabe I, Nagasaki M, Seo K, Yamashita H, Hosoya Y,
Ohsugi M, Tobe K, Kadowaki T, Nagai R, Sugiura S: In vivo imaging in mice
reveals local cell dynamics and inflammation in obese adipose tissue.
J Clin Invest 2008, 118:710–721.
22. Zahler S, Massoudy P, Hartl H, Hähnel C, Meisner H, Becker BF: Acute
cardiac inflammatory responses to postischemic reperfusion during
cardiopulmonary bypass. Cardiovasc Res 1999, 41:722–730.
23. Huang K, Li SQ, Wang WJ, Liu LS, Jiang YG, Feng PN, Wang YQ, Wang SM:
Oral FTY720 administration induces immune tolerance and inhibits early
development of atherosclerosis in apolipoprotein E-deficient mice.
Int J Immunopathol Pharmacol 2012, 25:397–406.
24. Keul P, Tölle M, Lucke S, von Wnuck Lipinski K, Heusch G, Schuchardt M,
van der Giet M, Levkau B: The sphingosine-1-phosphate analogue FTY720
reduces atherosclerosis in apolipoprotein E-deficient mice. Arterioscler
Thromb Vasc Biol 2007, 27:607–613.
25. Nofer JR, Bot M, Brodde M, Taylor PJ, Salm P, Brinkmann V, van Berkel T,
Assmann G, Biessen EA: FTY720, a synthetic sphingosine 1 phosphate
Iino et al. Lipids in Health and Disease 2014, 13:150 Page 10 of 10
http://www.lipidworld.com/content/13/1/150analogue, inhibits development of atherosclerosis in low-density
lipoprotein receptor-deficient mice. Circulation 2007, 115:501–508.
26. Yatomi Y, Ruan F, Hakomori S, Igarashi Y: Sphingosine-1-phosphate: a
platelet-activating sphingolipid released from agonist-stimulated human
platelets. Blood 1995, 86:193–202.
27. Yatomi Y: Plasma sphingosine 1-phosphate metabolism and analysis.
Biochim Biophys Acta 2008, 1780:606–611.
28. Kishimoto T, Matsuoka T, Imamura S, Mizuno K: A novel colorimetric assay
for the determination of lysophosphatidic acid in plasma using an
enzymatic cycling method. Clin Chim Acta 2003, 333:59–67.
doi:10.1186/1476-511X-13-150
Cite this article as: Iino et al.: Platelet-derived sphingosine 1-phosphate
induces migration of Jurkat T cells. Lipids in Health and Disease
2014 13:150.Submit your next manuscript to BioMed Central
and take full advantage of: 
• Convenient online submission
• Thorough peer review
• No space constraints or color ﬁgure charges
• Immediate publication on acceptance
• Inclusion in PubMed, CAS, Scopus and Google Scholar
• Research which is freely available for redistribution
Submit your manuscript at 
www.biomedcentral.com/submit
